Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy

NCT04905407 is registered in ClinicalTrials.gov with Syros Pharmaceuticals as lead sponsor.

NCT NCT04905407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04905407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Lead sponsor
Syros Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
August 26, 2021
Completion date
August 12, 2024
Enrollment
66 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia